Advertisement

Topics

Companies Related to "Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma" [Most Relevant Company Matches] RSS

18:50 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma" found in our extensive corporate database of over 50,000 company records.

Showing "Phenylbutyrate Treating Patients With Refractory Solid Tumors Lymphoma" Companies 1–25 of 4,400+

Extremely Relevant

Gloucester Pharmaceuticals

Gloucester Pharmaceuticals acquires clinical-stage oncology drug candidates and advances them through regulatory approval and commercialization. The Company’s first candidate, ISTODAX® (romidepsin), a novel histone deacetylase (HDAC) inhibitor, is FDA approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at le...


Relevant

Verastem Oncology

Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. Verastem Oncology is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint i...

The Lymphoma Research Foundation

The Lymphoma Research Foundation (LRF) is the nation's largest voluntary health organization devoted exclusively to funding lymphoma research and providing patients and healthcare professionals with critical information on the disease. LRF's mission is to eradicate lymphoma and serve those touched by this disease.


Cancer Genetics Incorporated

Cancer Genetics Incorporated is a leading genomics company focusing on genetic disease such as leukemia, lymphoma and solid tumors.

DACOGEN

DACOGEN is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and i...

Nereus Pharmaceuticals, Inc.

Nereus Pharmaceuticals pursues novel sources of chemical diversity to discover and develop new therapeutics. Using its unmatched expertise in marine microbiology to identify unique biologically active compounds, Nereus has two oncology drug candidates in clinical trials. Plinabulin (NPI-2358), a novel vascular disrupting agent, is being evaluated in patien...

Siamab Therapeutics, Inc.

Siamab Therapeutics, Inc. is a biopharmaceutical company developing novel cancer immunotherapies targeting cancer-specific carbohydrate antigens seen in multiple solid tumors. Siamab has developed a platform that enables the rapid discovery and development of therapeutic antibodies that bind with unprecedented specificity and affinity to this novel class o...

Techniclone International Corporation

TECHNICLONE CORPORATION is engaged in the research and development of unique therapeutics for the treatment of cancer: The company utilizes innovative targeting technologies to develop products capable of destroying cancerous tumors throughout the body. The Company's Tumor Necrosis Therapy (TNT) is designed to deliver high doses of radiation directly to the core of the tumor while causing minimal ...

Gemin X Pharmaceuticals, Inc.

Gemin X Pharmaceuticals, Inc., specializes in the discovery and development of novel target-based cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X's second compound GMX1777, is a potent, small molecule that specifically inhibits nicotinamide phosphoribosyl transferase (NAMPRT...

Lymphoma Research Foundation

The Lymphoma Research Foundation (LRF) is the nation's largest non-profit organization devoted to funding innovative research and providing people with lymphoma and healthcare professionals with up-to-date information about this type of cancer. LRF's mission is to eradicate lymphoma and serve those touched by this disease.

CerebralRx

Based in Yehud, Israel, CerebralRx was founded in 2010 as a spin-off of BioControl Medical to develop breakthrough implantable neuromodulation systems for the treatment of autonomic nervous system-related neurological disorders. The company’s flagship product is the FitNeS system, an implantable vagus nerve stimulation device for treating patients wit...

NeuroPace, Inc.

NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders by responsive brain stimulation. The company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide. Patients are currently being enrolled in a clinical trial of the company's Responsive N...

The Leukemia & Lymphoma Society (LLS)

The Leukemia & Lymphoma Society (® )(LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Washington Gas and Leukemia & Lymphoma Society (LLS)

The Leukemia & Lymphoma Society ® (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information a...

The Leukemia & Lymphoma Society and Reliant Energy

The Leukemia & Lymphoma Society ® (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and supp...

Threshold Pharmaceuticals, Inc.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effe...

The Cancer Support Community

Fielded by Harris Interactive and commissioned by the CSC, with support from Cephalon Oncology, the survey was distributed online within the United States and completed by 150 hematologists/oncologists and 133 indolent lymphoma patients, equaling 283 respondents in total. Indolent lymphoma patients participated in the survey from June 23-30, 2010, and hematologists/oncologists completed the surve...

Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (the "Company") is a biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading through...

PRAECIS PHARMACEUTICALS INCORPORATED

PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has a novel MetAP-2 inhibitor, PPI-2458, in clinical development for cancer indications, including non-Hodgkin's lymphoma and solid tumors, as well as an innovative drug discovery technology, Direct Sele...

Turnstone Biologics

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell va...

Allos Therapeutics, Inc.

Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN® (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in t...

Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigat...

WILEX AG

WILEX is a biopharmaceutical company developing novel cancer therapies for the treatment of various tumors including renal and breast cancer. Therapies are based upon biologic targets directly connected to cancer progression and pathogenesis in order to provide effective and well-tolerated treatment and enhance patients' quality of life.The company has a portfolio of cancer drug candidates ranging...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Erimos Technologies, LLC

Erimos has exclusive license for nordihydroguaiaretic acid (NDGA) derivatives from The Johns Hopkins University. We have developed a novel process to extract NDGA from the resin of the leaves of Larrea tridentata, a desert plant indigenous to the southwestern US and Mexico. EM-1421, our lead candidate, is a semi-synthetic derivative of NDGA. It is designed to target specific differences between no...


More From BioPortfolio on "Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks